Quantitative MRI and prostate cancer

Quantitative MRI for Prostate Cancer Detection and Monitoring AI Theater Presentation and RSNA 2021

(SAN DIEGO, Nov. 28, 2021)Cortechs.ai, creators of the first volumetric MRI AI application for clinical use, NeuroQuant, will be presenting new findings regarding the use of Quantitative MRI for Prostate Cancer Detection and Monitoring at this year’s Radiological Society of North America (RSNA) conference in Chicago. The presentation by Dr. Tyler Seibert MD, PhD will take place on Wednesday, December 1, 2021 at 2 p.m. in the AI Theater of the McCormick Place Convention Center. 

Tyler Seibert MD, PhD is a board-certified radiation oncologist, clinical translational researcher at UC San Diego, and one of Cortechs.ai’s Medical Advisory Board members. Seibert is experienced in complex data analysis, including development, validation, and translation of novel methods in both biomedical imaging and genetics. Innovations like OnQ Prostate are navigating cancer detection with data and precision that benefits physicians like Seibert with their analysis capabilities.

My top priority is to improve precision diagnosis and treatment of prostate cancer through quantitative imaging,” said Dr Seibert, “Together with our partners, Cortechs.ai has the ability to impart real innovation in the oncology MRI field.”

OnQ Prostate is FDA-cleared post-processing software that supports improved detection of clinically significant prostate cancer. The software leverages an advanced diffusion MRI technique called Restriction Spectrum Imaging (RSI), powered by AI, to enable faster, more accurate identification of restricted diffusion. Cortechs.ai will be stationed at booth 4542 showcasing and demonstrating NeuroQuant, NeuroQuant MS, OnQ Prostate. In addition, OnQ Neuro, a recently FDA cleared device for automated brain tumor segmentation with RSI technology, will also be introduced. Schedule a meeting in advance with a clinical specialist or account manager by clicking here

To learn more about Cortech.ai at RSNA 2021, visit www.cortechs.ai/rsna. Fellow AI-powered partner Subtle Medical, a healthcare technology company with deep learning solutions will be close-by at booth 4538 and you can request a meeting here. Cortechs.ai and Subtle Medical are a powerful team that contributes to real, fast, and objective results with imaging software. Together, our technology drastically reduces scan time and analysis.

About Cortechs.ai

Cortechs.ai is the leader in radiology AI applications, using cutting-edge advances in medical imaging to revolutionize disease screening and early detection so patients can enjoy longer, better lives. The company develops and markets breakthrough medical device software that quantifies and tracks neurodegenerative diseases and assists in the detection of clinically significant cancer. Cortechs.ai’s industry-leading brain imaging analysis provides neurologists, radiologists, oncologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and brain development abnormalities. The company has FDA-cleared products for use in the diagnosis of neurodegenerative and traumatic brain conditions and prostate cancer. Please visit www.cortechs.ai for further information and follow us on Twitter, LinkedIn, and Facebook.

More Resources

03/20/2025

Cortechs.ai Announces Strategic Distribution Partnership with Medical Horizons to Expand Presence in Italy, Turkey, and the Middle East

We are pleased to announce a strategic distribution partnership with Medical Horizons, a premier AI-powered medical device distributor based in Florence, Italy.

03/18/2025

Unlocking the Power of AI Imaging in Multiple Sclerosis: How NeuroQuant® MS Enhances Lesion Detection and Monitoring

Unlock the power of AI-driven imaging with NeuroQuant® MS—enhancing lesion detection, monitoring, and personalized care for Multiple Sclerosis.

03/09/2025

Advancing TBI Evaluation with AI-Driven MRI Analysis: A New Era in Brain Health

AI-driven MRI with NeuroQuant® enhances TBI assessment, tracks recovery, and supports better treatment decisions.

03/06/2025

Case Study: Leveraging NeuroQuant® for Accurate Diagnosis of Traumatic Brain Injury

This case highlights the power of advanced neuroimaging tools in delivering precise, evidence-based diagnostics to enhance patient care and clinical decisions.

02/26/2025

Traumatic Brain Injury in Athletes: The Role of the NeuroQuant and Automated Volumetric Tracking

NeuroQuant enables objective brain volume tracking for early TBI detection, recovery monitoring, and safer return-to-play decisions.

02/25/2025

OnQ™ Prostate Solution Enhances Collaboration and Improves MRI for Cancer Detection with RSI Technology

OnQ Prostate enhances MRI tissue characterization, improving sensitivity and specificity in cancer detection, & bridges gaps between radiologists and urologists
Scroll to Top